Deals In Depth: November 2014
Merck KGAA and Pfizer teamed up in an $850 million immunotherapy partnership; after fighting off Valeant’s efforts for months, Allergan ended up agreeing to a $65 billion acquisition by Actavis. Both biopharma and device financing were up vs. the previous month.
You may also be interested in...
A shift in investor sentiment in 2021 hit Everest hard when it was expanding the commercial team for cancer drug Trodelvy. Entering 2022, the sustained downturn in the capital market environment eventually changed the way the Chinese biotech considers launching drugs in the market.
A rare disclosure by China’s national health insurance payer shows how a major state-owned drug maker used its market-dominating position to dodge price-lowering schemes and increase drug prices more than 10-fold.
What are the special regulatory pathways that allow the use of unapproved devices? Asia Regulatory Professionals Association’s Rachel Lee and Helena Baric supply the answer, with reference to the systems used in the US and Singapore.